Correlation between Serum Levels of Sympathetic Nerve Activity Markers and Sleep Quality and Cognitive Function in Patients with Chronic Insomnia Disorder

Authors

  • Ting Hu Department of Sleep Disorders, the Affiliated Chaohu Hospital of Anhui Medical University, Hefei (Chaohu), China
  • Xuan Song Department of Sleep Disorders, the Affiliated Chaohu Hospital of Anhui Medical University, Hefei (Chaohu), China
  • Yi-Jun Ge Department of Sleep Disorders, the Affiliated Chaohu Hospital of Anhui Medical University, Hefei (Chaohu), China
  • Ping Zhang Department of Sleep Disorders, the Affiliated Chaohu Hospital of Anhui Medical University, Hefei (Chaohu), China
  • Xue-Yan Li Department of Sleep Disorders, the Affiliated Chaohu Hospital of Anhui Medical University, Hefei (Chaohu), China
  • Xiao-Yi Kong Department of Sleep Disorders, the Affiliated Chaohu Hospital of Anhui Medical University, Hefei (Chaohu), China
  • Gui-Hai Chen Department of Sleep Disorders, the Affiliated Chaohu Hospital of Anhui Medical University, Hefei (Chaohu), China

Keywords:

?-amylase, Cognition, Copeptin, Insomnia

Abstract

Abstract: Objectives: To explore the changes of the serum levels of copeptin and ?-amylase and the correlations with sleep quality and cognition function in the patients with chronic insomnia disorder (CID).

Methods: Fifty-seven CID patients and thirty healthy controls were enrolled continuously. Pittsburgh Sleep Quality Index (PSQI), polysomnography (PSG) and Pre-Sleep Arousal Scale (PSAS) were used to assess the insomnia severity and cognitive and somatic manifestations of arousal experienced at bedtime. Montreal Cognitive Assessment scale (MoCA) and Nine-Box Maze were used to respectively assess general cognition and memories. The serum levels of copeptin and ?-amylase were detected using Enzyme-Linked ImmunoSorbent Assay.

Results: Compared to the controls, the CID patients had increased PSQI and PSAS scores (Z=?7.678 and ?7.350; Ps<0.001), decreased MoCA score (t=?4.625, P<0.001), increased numbers of errors in the object working, spatial working and object recognition (Z=?2.099, ?3.935 and ?2.266; Ps<0.05) memories, and elevated serum levels of copeptin and ?-amylase (t=5.414 and 5.597, P <0.001). In the CID patients?the level of copeptin positively correlated with PSQI and PSAS scores (r=0.338 and 0.316; Ps<0.05), and PSG sleep latency, wake time and N1% (r=0.324, 0.325 and 0.278, Ps<0.05), and negatively correlated with PSG N 2% (r=?0.279, Ps<0.05). Alpha-amylase was positively correlated with waking numbers in PSG (r=0.293, P< 0.05). Multiple linear regression analysis showed that copeptin level affected PSQI score and PSG sleep latency (P<0.05).

Conclusions: The serum levels of copeptin and ?-amylase elevated in the CID patients, and the serum levels of copeptin may be associated with the poor sleep quality, especially in the individuals of initial sleep difficulties.

References

Chen GH and Zhao ZX. Insomnia. In: Zhao ZX editor-in-chief. Sleep medicine [M]. First edition, Beijing, people's health publishing house 2016; 83-88.

Pang R, Guo R, Wu X, et al. Altered regional homogeneity in chronic insomnia disorder with or without cognitive impairment. AJNR Am J Neuroradiol 2018; 39(4): 742-747. https://doi.org/10.3174/ajnr.A5587

Bianchi MT. Chronic Insomnia. Semin Neurol. 2017; 37(4): 433-438. https://doi.org/10.1055/s-0037-1605344

Riemann D, Spiegelhalder K, Feige B, et al. The hyperarousal model of insomnia: a review of the concept and its evidence. Sleep Med Rev 2010; 14(1): 19-31. https://doi.org/10.1016/j.smrv.2009.04.002

Tobaldini E, Costantino G, Solbiati M, et al. Sleep, sleep deprivation, autonomic nervous system and cardiovascular diseases. Neurosci Biobehav Rev 2017; 74(Pt B): 321-329. https://doi.org/10.1016/j.neubiorev.2016.07.004

Zhao ZQ, Li YP, Xiang XX, et al. Pathophysiology and cognitive behavioral therapy of chronic insomnia [J]. Chin J Clin Pharmacol Ther, 2021; 26(5): 481-486.

Xia L, Chen GH, Li ZH, et al. Alterations in hypothalamus-pituitary-adrenal/thyroid axes and gonadotropin-releasing hormone in the patients with primary insomnia: a clinical research. PLoS One 2013; 8 (8): e71065. https://doi.org/10.1371/journal.pone.0071065

Thomson F, Craighead M. Innovative approaches for the treatment of depression: targeting the HPA axis. Neurochem Res 2008; 33(4): 691-707. https://doi.org/10.1007/s11064-007-9518-3

Ozben S, Guvenc TS, Huseyinoglu N, et al. Low serum copeptin levels in patients with obstructive sleep apnea. Sleep Breath, 2013, 17(4): 1187-1192. https://doi.org/10.1007/s11325-013-0822-7

Christ-Crain M. Vasopressin and copeptin in health and disease. Rev Endocr Metab Disord 2019; 20(3): 283-294. https://doi.org/10.1007/s11154-019-09509-9

Ç?narka H, Kayhan S, Karata? M, et al. Copeptin: a new predictor for severe obstructive sleep apnea. Ther Clin Risk Manag 2015; 11: 589-594. https://doi.org/10.2147/TCRM.S80779

Bosch JA, Veerman EC, de Geus EJ, Proctor GB. ?-Amylase as a reliable and convenient measure of sympathetic activity: don't start salivating just yet!. Psychoneuroendocrinology 2011; 36(4): 449-453. https://doi.org/10.1016/j.psyneuen.2010.12.019

Sateia MJ. International classification of sleep disorders?third edition: highlights and modifications. Chest 2014; 146(5): 1387-1394. https://doi.org/10.1378/chest.14-0970

Buysse DJ, Reynolds CF 3rd, Monk TH, et al. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res 1989; 28(2): 193-213. https://doi.org/10.1016/0165-1781(89)90047-4

Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56-62. https://doi.org/10.1136/jnnp.23.1.56

Nicassio PM, Mendlowitz DR, Fussell JJ, et al. The phenomenology of the pre-sleep state: the development of the pre-sleep arousal scale. Behav Res Ther 1985; 23(3): 263- 271. https://doi.org/10.1016/0005-7967(85)90004-X

Chen X, Zhang R, Xiao Y, et al. Reliability and validity of the Beijing version of the Montreal Cognitive Assessment in the evaluation of cognitive function of adult patients with OSAHS. PLoS One 2015; 10(7): e0132361. https://doi.org/10.1371/journal.pone.0132361

Wei QG, Chen GH, Xia L, et al. The differences of memories and sleep parameters and their correlations in patients with insomnia disorder in different subtypes: a clinical study. Chin J Neurol 2015; 48(9): 763-767.

Grimaldi D, Goldstein MR, Carter JR. Insomnia and cardiovascular autonomic control. Auton Neurosci 2019; 220: 102551. https://doi.org/10.1016/j.autneu.2019.05.003

Schinke C, Hesse S, Rullmann M, et al. Central noradrenaline transporter availability is linked with HPA axis responsiveness and copeptin in human obesity and non?obese controls. Stress 2019; 22(1): 93-102. https://doi.org/10.1080/10253890.2018.1511698

Szczepanska-Sadowska E, Zera T, Sosnowski P, et al. Vasopressin and related peptides; potential value in diagnosis, prognosis and treatment of clinical disorders. Curr Drug Metab 2017; 18(4): 306-345. https://doi.org/10.2174/1389200218666170119145900

Gu X, Gu P, Liu YH, et al. Correlation of sleep quality, anxiety, depression and sympathetic skin response in chronic insomnia. Chin J Neurol 2017; 50(9): 665-670.

Carter JR, Grimaldi D, Fonkoue IT, et al. Assessment of sympathetic neural activity in chronic insomnia: evidence for elevated cardiovascular risk. Sleep 2018; 41(9): zsy126. https://doi.org/10.1093/sleep/zsy126

Jarrin DC, Chen IY, Ivers H, et al. The role of vulnerability in stress?related insomnia, social support and coping styles on incidence and persistence of insomnia. J Sleep Res 2014; 23(6): 681-688. https://doi.org/10.1111/jsr.12172

Palagini L, Moretto U, Novi M, et al. Lack of resilience is related to stress?related sleep reactivity, hyperarousal, and emotion dysregulation in insomnia disorder. J Clin Sleep Med 2018; 14(5): 759-766. https://doi.org/10.5664/jcsm.7100

Lozi? M, Šarenac O, Murphy D, et al. Vasopressin, central autonomic control and blood pressure regulation. Curr Hypertens Rep 2018; 20(2): 11. https://doi.org/10.1007/s11906-018-0811-0

Gehrman PR, Hall M, Barilla H, et al. Stress reactivity in insomnia. Behav Sleep Med 2016; 14(1): 23-33. https://doi.org/10.1080/15402002.2014.940112

Nater UM, Rohleder N. Salivary alpha?amylase as a non?invasive biomarker for the sympathetic nervous system: current state of research. Psychoneuroendocrinology 2009; 34(4): 486-496. https://doi.org/10.1016/j.psyneuen.2009.01.014

Zhang P, Tan CW, Chen GH, et al. Patients with chronic insomnia disorder have increased serum levels of neurofilaments, neuron?specific enolase and S100B: does organic brain damage exist? Sleep Med 2018; 48: 163-171. https://doi.org/10.1016/j.sleep.2017.12.012

Downloads

Published

2021-12-06

Issue

Vol. 8 No. 2 (2021)

Section

Articles

License

Policy for Journals/Articles with Open Access

Authors who publish with this journal agree to the following terms:
    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

  1. Authors are permitted and encouraged to post links to their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work

Policy for Journals / Manuscript with Paid Access

Authors who publish with this journal agree to the following terms:
    1. Publisher retain copyright .

  1. Authors are permitted and encouraged to post links to their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work .